getpdf NLM PubMed Logo https://doi.org/10.17113/ftb.63.03.25.8691                 

COX-2 Inhibition by Bioactive Peptides from Peanut Worm (Siphonosoma australe) Collagen Through in vitro Digestion Simulation

Suwarjoyowirayatno1,2orcid tiny, Chusnul Hidayat1orcid tiny, Tutik Dwi Wahyuningsih3orcid tiny and Retno Indrati1*orcid tiny

1Department of Food and Agricultural Product Technology, Faculty of Agricultural Technology, Universitas Gadjah Mada, Flora Street, Bulaksumur, Yogyakarta 55281, Indonesia

2Department of Fish Product Technology, Faculty of Fisheries and Marine Science, Universitas Halu Oleo, H.E.A. Mokodompit Street, Kendari 93231, Indonesia

3Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Gadjah Mada, Sekip Utara, Bulaksumur, Yogyakarta 55281, Indonesia

cc by Copyright © 2025 This is a Diamond Open Access article published under CC-BY licence. Copyright remains with the authors, who grant third parties the unrestricted right to use, copy, distribute and reproduce the article as long as the original author(s) and source are acknowledged.

Article history:

Received: 6 May 2024

Accepted: 6 March 2025

Published online: 31 August 2025

Keywords:

bioactive peptide; COX-2 inhibition; digestion simulation; molecular docking; peanut worm collagen; Siphonosoma austral

E WEB Goal 03E WEB Goal 14
The content of this publication has not been approved by the United Nations and does not reflect the views of the United Nations or its officials or Member States.

Summary:

Research background. Chronic, unregulated inflammation is a crucial factor in the development of numerous diseases and is closely linked to the increased expression of cyclooxygenase-2 (COX-2). While various bioactive peptides from marine organisms have shown COX-2 inhibitory effects, peptides derived from the collagen of the peanut worm (Siphonosoma australe) have not yet been demonstrated. The aim of this study is to investigate the potential COX-2 inhibitory activity of peanut worm collagen by simulated digestion in vitro with pepsin-pancreatin followed by molecular docking.

Experimental approach. During simulated in vitro digestion, commercial pepsin (at pH=3) and pancreatin (at pH=7.5) were applied for 240 min at 37 °C to evaluate the degree of hydrolysis, peptide concentration and COX-2 inhibitory activity. The samples with the most significant COX-2 inhibitory activity were then separated into fractions and identified.

Results and conclusions. The 210-minute simulated digestion in vitro showed the highest COX-2 inhibitory activity (64.31 %). This result was confirmed by the increased degree of hydrolysis (DH) and peptide concentrations observed during the simulated in vitro digestion. The peptide fraction of <1 kDa had the highest inhibitory activity (89.05 %) and was subsequently subjected to sequencing analysis. Three novel peptides, ADIAGQAAQVLR, LNNEITTLR and VGTVEK, were identified and confirmed to contain crucial amino acids and therefore verified as COX-2 inhibitors. VGTVEK has the most potent interaction, as shown by the lowest binding energy (−4.41 kcal/mol). The molecular docking revealed that VGTVEK (631.35 Da) binds to the active site of COX-2 and forms hydrogen bonds with Gln178, Leu338, Ser339, Tyr371, Ile503, Phe504, Val509 and Ser516 and hydrophobic interactions with Met99, Val102, Val330, Ile331, Tyr334, Val335, Leu345, Trp373, Leu517 and Leu520. Other biological activities of the produced peptides included ACE inhibitors, dipeptidyl peptidase-IV (DPP-IV) inhibitors and α-glucosidase inhibitors. After toxicity prediction, the peptides were classified as non-toxic.

Novelty and scientific contribution. The study found that peptides derived from peanut worm collagen have the potential to be novel, natural agents for anti-inflammatory therapy. Their broader application in functional foods, nutraceuticals and pharmaceuticals could provide new options for people suffering from inflammation and support both treatment and maintenance of overall health.

*Corresponding author: +62811267259
  +62274589797
  This email address is being protected from spambots. You need JavaScript enabled to view it.